What are the criteria for cGVHD Diagnosis?
Dr Daniel R Couriel
For the diagnosis of chronic graft-versus-host disease (cGVHD), the main criteria are clinical. Nowadays, the definition of cGVHD no longer has to do with GVHD diagnosed after day 100, but more with a clinical-criteria definition. That, basically, is what you go by. You can biopsy different tissues to confirm cGVHD, but I use biopsy in a minority of patients. Usually, clinical presentation is sufficient. There are differential diagnoses, such as, on occasion, infection, although infection and cGVHD can coexist, but usually that is all. Unfortunately, we do not have other biomarkers to diagnose or predict it or to follow its clinical course. I am sure that Jamie will allude to biomarkers when he talks about acute GVHD (aGVHD), but that is how I diagnose cGVHD.
What is the basis for the treatment of cGVHD with photopheresis?
What organs are involved in cGVHD?
How do you diagnose aGVHD?
Which patients with cGVHD can benefit from a referral for photopheresis?
Which patients with aGVHD can benefit from a referral for photopheresis?
What is the basis for the treatment of aGVHD with photopheresis?
What are the clinical features of cGVHD that suggest referral for photopheresis would be appropriate?
Can cGVHD patients benefit from early referral for photopheresis?
How can you diagnose SOT rejection?
When may photopheresis therapy be indicated for SOT rejection?
What may be the benefits of early treatment with photopheresis in SOT rejection?
How does the THERAKOS™ CELLEX™ Photopheresis System operate?
What happens when photopheresis-treated cells are added to an In Vivo aGVHD model?